CPHI stock touches 52-week high of $1.4 amid market fluctuations

China Pharma Holdings Inc. (CPHI) stock has reached a notable milestone, hitting a 52-week high of $1.4. This peak comes amidst a turbulent period for the market, signaling a significant moment for the company’s valuation. InvestingPro data reveals concerning fundamentals, with revenue declining 35% and an EBITDA of -$1.97M in the last twelve months. Despite this recent high, CPHI has experienced a considerable decline over the past year, with a 1-year change showing a decrease of -57.87%. This contrast highlights the volatile journey for shareholders and underscores the challenges faced by the company in a competitive pharmaceutical landscape. The 52-week high serves as a beacon of potential recovery and investor interest, even as the broader context reflects a year of substantial losses. According to InvestingPro, the company’s financial health score is rated as WEAK, with negative gross margins and a concerning current ratio of 0.65. InvestingPro subscribers have access to 12 additional key insights about CPHI’s financial position.

In other recent news, China Pharma Holdings Inc. has announced a 1-for-10 reverse stock split of its common stock, effective April 15, 2025. This corporate action was unanimously approved by the Board of Directors and ratified by stockholders at the Annual Meeting for the fiscal year ended December 31, 2023. The reverse stock split will convert every 10 shares of China Pharma’s issued and outstanding common stock into one share. Shareholders will receive rounded-up whole shares in the event of fractional entitlements. This move is intended to affect all shareholders uniformly and will not alter any shareholder’s percentage interest in the company’s outstanding common stock, aside from minor adjustments due to rounding. The company’s shares will continue to trade on the NYSE American under the ticker symbol "CPHI" with a new CUSIP number starting from the market open on the specified date. This development reflects China Pharma’s ongoing efforts to manage its equity structure effectively.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.